Get started
Author

Julia Nguyen

ORCID: 0000-0001-5130-1290
Observed ORCID: 0000-0001-5130-1290
OpenAlex ID: A5044638384
High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study
2025 · Jorge Castillo, Gottfried von Keudell, et al. · Blood · 5
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia
2025 · Jorge J. Castillo, Alberto Guijosa, et al. · Blood Advances · 5
Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.
2025 · Shayna Sarosiek, Mary Kwok, et al. · Blood · 3
PDF
Assessing the Association Between Time to Surgery and Survival in Sinonasal Squamous Cell Carcinoma
2023 · Julia Nguyen, Rushi Patel, et al. · The Laryngoscope · 3
PDF
Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications
2025 · Alberto Guijosa, Nickolas Tsakmaklis, et al. · Blood · 2
PDF
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
2026 · Jorge J. Castillo, Andrew R. Branagan, et al. · American Journal of Hematology · 1
Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia
2025 · Jorge Castillo, Andrew Branagan, et al. · Blood · 1
PDF
LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK
2025 · Maria Luisa Guerrera, Abigail Peachey, et al. · Blood
PDF
275 All-in-one CAR T cell platform for safe and effective targeting of metastatic castration-resistant prostate cancer
2025 · Nour Shobaki, Yutong Deng, et al. · Regular and Young Investigator Award Abstracts
PDF
IBCL-884: Zanubrutinib Dosing and Mutational Status Impact Response and Outcomes in Waldenström Macroglobulinemia
2025 · Alberto Guijosa, Nicholas Tsakmaklis, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-884 Zanubrutinib Dosing and Mutational Status Impact Response and Outcomes in Waldenström Macroglobulinemia
2025 · Alberto Guijosa, Nicholas Tsakmaklis, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 11
Citation count: 20
H-index: 3
I10-index:
Year
Topic
Type